Contrasting Portage Biotech (NASDAQ:ATON) & Evofem Biosciences (NASDAQ:EVFM)

Evofem Biosciences (NASDAQ:EVFM) and Portage Biotech (NASDAQ:ATON) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares Evofem Biosciences and Portage Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
Portage Biotech	N/A	N/A	N/A

Risk and Volatility

Evofem Biosciences has a beta of -1.33, meaning that its share price is 233% less volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.

Insider and Institutional Ownership

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 13.4% of Portage Biotech shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Evofem Biosciences and Portage Biotech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39 million	0.09	$52.98 million	($0.07)	-0.11
Portage Biotech	N/A	N/A	-$6.77 million	($8.18)	-0.04

Evofem Biosciences has higher revenue and earnings than Portage Biotech. Evofem Biosciences is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Evofem Biosciences and Portage Biotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evofem Biosciences	0	0	0	0	0.00
Portage Biotech	1	0	1	0	2.00

Portage Biotech has a consensus price target of $2.00, suggesting a potential upside of 502.41%. Given Portage Biotech’s stronger consensus rating and higher possible upside, analysts plainly believe Portage Biotech is more favorable than Evofem Biosciences.

Summary

Portage Biotech beats Evofem Biosciences on 8 of the 13 factors compared between the two stocks.

About Evofem Biosciences

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

About Portage Biotech

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.